Aimmune Therapeutics Inc EV/Sales
What is the EV/Sales of Aimmune Therapeutics Inc?
The EV/Sales of Aimmune Therapeutics Inc is 3,769.86
What is the definition of EV/Sales?
Enterprise value to sales ratio compares a company’s total value to its sales.
ttm (trailing twelve months)
Enterprise value/sales is a valuation ratio that compares the company's enterprise value to its annual sales. It indicates the company's capacity to generate free cash flow. In general, the lower the ratio, the cheaper the company is.
EV/Sales is most often calculated as cash and cash equivalents subtracted from the sum of market capitalization and debt and divided by annual sales. Many analysts consider EV/sales to be a more accurate metric than Price/Sales as it considers both debt and equity holders in its calculation. One of the limitations of the calculation is that sales do not take into account a company's taxes or expenses.
EV/Sales of companies in the Health Care sector on NASDAQ compared to Aimmune Therapeutics Inc
Companies with ev/sales similar to Aimmune Therapeutics Inc
- Sollensys has EV/Sales of 3,673.28
- Chatham Rock Phosphate has EV/Sales of 3,674.75
- Adverum Biotechnologies Inc has EV/Sales of 3,700.64
- BrainChip Ltd has EV/Sales of 3,716.87
- Transport of India has EV/Sales of 3,751.48
- Cobalt Blue has EV/Sales of 3,760.97
- Aimmune Therapeutics Inc has EV/Sales of 3,769.86
- Monaker Inc has EV/Sales of 3,780.80
- Pancontinental Oil & Gas NL has EV/Sales of 3,794.33
- Eastern Metals has EV/Sales of 3,837.78
- Wilton Resources has EV/Sales of 3,857.68
- Highway 50 Gold has EV/Sales of 3,878.14
- Breaker Resources NL has EV/Sales of 3,890.98